TY - JOUR
T1 - Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion
T2 - A report on 62 cases
AU - Braun, Thorsten
AU - de Botton, Stéphane
AU - Taksin, Anne Laure
AU - Park, Sophie
AU - Beyne-Rauzy, Odile
AU - Coiteux, Valérie
AU - Sapena, Rosa
AU - Lazareth, Anne
AU - Leroux, Geneviève
AU - Guenda, Khaled
AU - Cassinat, Bruno
AU - Fontenay, Michaela
AU - Vey, Norbert
AU - Guerci, Agnès
AU - Dreyfus, François
AU - Bordessoule, Dominique
AU - Stamatoullas, Aspasia
AU - Castaigne, Sylvie
AU - Terré, Christine
AU - Eclache, Virginie
AU - Fenaux, Pierre
AU - Adès, Lionel
PY - 2011/7/1
Y1 - 2011/7/1
N2 - Isolated 20q deletion is common in MDS and considered of good prognosis, but no large series have been reported. We compared characteristics of 62 MDS patients with isolated del 20q, 36 patients with del 20q and other cytogenetic abnormalities, and 1335 MDS patients without del20q. Significant differences between MDS with isolated del 20q and patients without del 20q were lower platelet count (mean 144 vs. 196 G/l, p = 0.005), lower marrow blast count (mean 3.9% vs. 5.6%, p = 0.0008), and higher reticulocyte count (mean 72.5 vs. 51.7 G/l, p = 0.04). Ten (16%) patients with isolated del 20q had Hb > 12. g/dl and platelets <100 G/l, compared to 7.3% of patients without del 20q (p = 0.025). Review of marrow slides of those 10 patients showed that could be readily identified as MDS prior to cytogenetics. Fourteen percent of patients with isolated del 20q progressed to AML compared to 11% with one and 24% with several additional abnormalities. Median survival was 54 months in patients with isolated del 20q, not reached and 12 months for del 20q with one and several additional abnormalities, respectively (p = 0.035) confirming the favorable prognosis of del 20q without complex abnormalities.
AB - Isolated 20q deletion is common in MDS and considered of good prognosis, but no large series have been reported. We compared characteristics of 62 MDS patients with isolated del 20q, 36 patients with del 20q and other cytogenetic abnormalities, and 1335 MDS patients without del20q. Significant differences between MDS with isolated del 20q and patients without del 20q were lower platelet count (mean 144 vs. 196 G/l, p = 0.005), lower marrow blast count (mean 3.9% vs. 5.6%, p = 0.0008), and higher reticulocyte count (mean 72.5 vs. 51.7 G/l, p = 0.04). Ten (16%) patients with isolated del 20q had Hb > 12. g/dl and platelets <100 G/l, compared to 7.3% of patients without del 20q (p = 0.025). Review of marrow slides of those 10 patients showed that could be readily identified as MDS prior to cytogenetics. Fourteen percent of patients with isolated del 20q progressed to AML compared to 11% with one and 24% with several additional abnormalities. Median survival was 54 months in patients with isolated del 20q, not reached and 12 months for del 20q with one and several additional abnormalities, respectively (p = 0.035) confirming the favorable prognosis of del 20q without complex abnormalities.
KW - Del 20q
KW - Immunologic thrombocytopenic purpura
KW - Myelodysplastic syndromes
KW - Thrombocytopenia
KW - WHO classification
UR - http://www.scopus.com/inward/record.url?scp=79958726106&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2011.02.008
DO - 10.1016/j.leukres.2011.02.008
M3 - Article
C2 - 21396711
AN - SCOPUS:79958726106
SN - 0145-2126
VL - 35
SP - 863
EP - 867
JO - Leukemia Research
JF - Leukemia Research
IS - 7
ER -